We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.5%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.46B
AUM Growth
-$315M
Cap. Flow
+$85.5M
Cap. Flow %
1.32%
Top 10 Hldgs %
48.84%
Holding
76
New
7
Increased
23
Reduced
12
Closed
8

Top Buys

1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$362M
2
DYN icon
Dyne Therapeutics
DYN
+$95.8M
3
INSM icon
Insmed
INSM
+$68.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
GKOS icon
Glaukos
GKOS
+$34.8M

Top Sells

1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$163M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$149M
3
SYK icon
Stryker
SYK
+$115M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$94M
5
TMO icon
Thermo Fisher Scientific
TMO
+$64.2M

Sector Composition

1 Healthcare 99.86%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
1
Madrigal Pharmaceuticals
MDGL
$12.8B
$537M 8.31%
1,915,862
+1,518,815
+383% +$362M
RCKT icon
2
Rocket Pharmaceuticals
RCKT
$376M
$381M 5.9%
17,687,772
– –
AXSM icon
3
Axsome Therapeutics
AXSM
$11.8B
$373M 5.78%
4,634,331
+141,652
+3% +$10.5M
RNAM
4
DELISTED
Avidity Biosciences
RNAM
$360M 5.57%
8,806,838
+836,569
+10% +$24M
ARGX icon
5
argenx
ARGX
$53.8B
$281M 4.36%
654,430
-12,765
-2% -$4.89M
NTRA icon
6
Natera
NTRA
$38.9B
$281M 4.35%
2,593,323
– –
MRUS
7
DELISTED
Merus
MRUS
$247M 3.82%
4,169,393
+60,000
+1% +$2.91M
INSM icon
8
Insmed
INSM
$23.5B
$244M 3.78%
3,640,108
+1,775,000
+95% +$68.8M
PTCT icon
9
PTC Therapeutics
PTCT
$6.52B
$226M 3.5%
7,393,127
-30,843
-0.4% -$999K
DYN icon
10
Dyne Therapeutics
DYN
$3.92B
$225M 3.49%
6,387,138
+3,295,551
+107% +$95.8M
ACAD icon
11
Acadia Pharmaceuticals
ACAD
$4.38B
$223M 3.45%
13,707,506
-121,809
-0.9% -$1.97M
BRKR icon
12
Bruker
BRKR
$8.86B
$220M 3.4%
3,444,095
+100,000
+3% +$7.53M
MASI
13
DELISTED
Masimo
MASI
$184M 2.85%
1,462,400
– –
PTGX icon
14
Protagonist Therapeutics
PTGX
$9.06B
$183M 2.84%
5,286,404
-29,110
-0.5% -$853K
ALKS icon
15
Alkermes
ALKS
$8.79B
$170M 2.63%
7,056,988
+1,002,708
+17% +$24.6M
IMCR icon
16
Immunocore
IMCR
$1.78B
$165M 2.56%
4,869,798
-1,149,843
-19% -$58.6M
CYTK icon
17
Cytokinetics
CYTK
$10.9B
$147M 2.28%
2,721,158
+196,078
+8% +$11.8M
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.88B
$134M 2.07%
3,259,927
-3,827,188
-54% -$163M
PEN icon
19
Penumbra
PEN
$12.5B
$134M 2.07%
742,105
+66,217
+10% +$13.2M
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$127M 1.97%
5,431,985
– –
ESTA icon
21
Establishment Labs
ESTA
$2.72B
$122M 1.88%
2,675,703
– –
IMTX icon
22
Immatics
IMTX
$1.31B
$116M 1.8%
10,000,000
– –
RDNT icon
23
RadNet
RDNT
$4.89B
$109M 1.69%
1,856,010
+155,460
+9% +$8.44M
APGE icon
24
Apogee Therapeutics
APGE
$10.1B
$107M 1.65%
2,712,096
+244,505
+10% +$11.9M
TARS icon
25
Tarsus Pharmaceuticals
TARS
$2.61B
$92.8M 1.44%
3,412,486
+140,145
+4% +$4.71M
1
2 3 4

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q2 2024 Portfolio in Review

As of Q2 2024, RTW Investments held 76 positions worth $6.46B, down 4.7% from $6.77B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

RTW Investments's Q2 2024 filing shows 7 new, 23 increased, 12 reduced and 8 closed positions. Its largest new stake was Cullinan Oncology: 1,052,630 shares worth $18.4M. The largest sale was Ultragenyx Pharmaceutical, an estimated $163M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q2 2024 buy was Cullinan Oncology: 1,052,630 shares worth $18.4M.
  • RTW Investments added most to Madrigal Pharmaceuticals in Q2 2024, an estimated $362M increase.
  • RTW Investments's biggest Q2 2024 reduction was Ultragenyx Pharmaceutical, cutting an estimated $163M.
  • RTW Investments fully exited Avadel Pharmaceuticals in Q2 2024, selling an estimated $149M.
  • RTW Investments's ten largest holdings make up 49% of its $6.46B portfolio in Q2 2024.
  • RTW Investments opened 7 new positions and closed 8 in Q2 2024.
  • RTW Investments's portfolio value fell 4.7% quarter-over-quarter to $6.46B.

Based on RTW Investments's 13F filing for Q2 2024, filed 14 Aug 2024.